GODAVARI DRUGS LTD.

Godavari Drugs Ltd has announced that its Board of Directors will convene on August 24, 2026. The primary agenda item is the consideration and approval of the Un-audited Financial Results for the first quarter ended June 30, 2026, along with the limited review report. Additionally, the board will discuss any other business as permitted. The company also confirmed the closure of its trading window from July 1, 2026, which will reopen 48 hours after the financial results are declared.

Godavari Drugs Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is effective from July 1, 2026, and will remain in effect until 48 hours after the declaration of the un-audited financial results for the quarter ending June 30, 2026. The decision aligns with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. Designated persons and their immediate relatives are prohibited from trading during this period to prevent potential insider trading.

Godavari Drugs Ltd's Board Meeting on May 27, 2026, approved the audited financial results for the quarter and financial year ended March 31, 2026. The board also approved the appointment of M/s. S.K. Lahoti Associates as Internal Auditors and M/S. Bharathula & Associates as Cost Auditors for FY 2026-27, subject to shareholder ratification. The 38th Annual General Meeting is scheduled for September 25, 2026, via video conferencing.

Godavari Drugs Ltd. has announced the approval of its audited financial results for the quarter and financial year ended March 31, 2026, during a board meeting held on May 27, 2026. The board also approved the appointment of M/s. S.K. Lahoti Associates as Internal Auditors and M/S. Bharathula & Associates as Cost Auditors for the financial year 2026-27. The 38th Annual General Meeting is scheduled for September 25, 2026, via video conferencing.

Godavari Drugs Ltd has scheduled a Board of Directors meeting on May 27, 2026, to consider and approve the audited standalone financial results for the quarter and financial year ended March 31, 2026. The trading window, which was closed from April 1, 2026, will reopen 48 hours after the declaration of these results.

Godavari Drugs Ltd responded to a BSE query dated April 17, 2026, regarding significant movement in its share price. The company stated that it has complied with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, by making all necessary and timely disclosures of price-sensitive information. Godavari Drugs confirmed that it is not aware of any undisclosed price-sensitive information that would be required to be intimated to the stock exchanges. The company attributed the movement in its share price entirely to market conditions, over which it has no control.

Priyanka Jaju, a promoter of Godavari Drugs Limited, has acquired 1,00,000 Convertible Warrants through a preferential issue on 18th March 2026. This acquisition is in accordance with Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The warrants are divided into 75,30,500 fully paid-up equity shares of Rs. 10/- each.

Prashant Shrimal, a part of the promoter group of Godavari Drugs Ltd, has acquired 1.12 lakh shares through a preferential issue on 18th March 2026. This acquisition amounts to 1.09% of the total diluted voting rights of the company.

Godavari Drugs Ltd, in accordance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, and the company's Code of Conduct, has announced the closure of the trading window for dealing in the company's securities by its designated persons and their immediate relatives. The closure will be effective from Wednesday, April 01, 2026, and will remain in force until 48 hours after the declaration of the Audited Financial Results for the quarter and financial year ending March 31, 2026. The date of the Board Meeting for consideration and approval of the Audited Financial Results will be intimated to the Stock Exchange in due course.

Kamala Jaju, a promoter of Godavari Drugs Limited, has acquired 3,00,000 (Three Lakhs Only) Convertible Warrants by way of preferential issue on 18th March 2026. This acquisition is in accordance with Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The warrants are divided into 75,30,500 fully paid-up equity shares of Rs. 10/- each, 1,01,27,435 equity shares of Rs. 10/- each, and 1,24,87,500 fully paid-up equity shares of Rs. 10/- each. This acquisition increases Kamala Jaju's total share/voting capital to 12.08% and diluted share/voting capital to 12.08%.